Abstract: A header assembly includes an insulative housing having a plurality of walls defining an interior cavity extending along a mating axis, and a plurality of contacts within the cavity and extending through one of the walls to an exterior of the housing for surface mounting to a circuit board. The insulative housing includes at least one alignment rib extending on an exterior surface thereof in a direction substantially perpendicular to the mating axis. The contacts are formed against and abutting the alignment rib, thereby ensuring coplanarity of the contacts for surface mounting to a circuit board.

Abstract: A header assembly includes an insulative housing comprising a plurality of walls defining an interior cavity, and a plurality of contacts within said cavity and extending through one of the walls to an exterior of the housing for surface mounting to a circuit board. The insulating housing comprises at least one alignment rib extending on an exterior surface thereof. The contacts are formed to abut the alignment rib, thereby ensuring coplanarity of the contacts for surface mounting to a circuit board.

Abstract: A system for treating a fluid comprising a treatment chamber; a light source for emitting light, such that at least a portion of the light travels within the treatment chamber; and a treatment area within the treatment chamber; wherein a flow profile of the fluid in the treatment area matches the fluence profile of the light that travels within the treatment area. An apparatus for providing a substantially uniform light treatment of a flowing fluid by providing a light source or sources and establishing (or controlling) the flow such that the combination of light intensity and flow velocity provides substantially uniform treatment (i.e. the faster moving fluid streams are treated at higher intensity and the slower moving fluid streams are treated at lower intensity).

Abstract: The invention concerns a oligomeric MHC complex comprising at least two chimeric proteins, said chimeric proteins comprising a first section derived from an MHC peptide chain or a functional part thereof and a second section comprising an oligomerising domain derived from an oligomer-forming coiled-coil protein, wherein formation of the oligomeric MHC complex occurs by oligomerisation at the oligomerising domain of the chimeric proteins, and wherein at least two of the first sections are derived from the same MHC peptide chain. The invention also concerns a chimeric protein comprising a first section derived from an MHC peptide chain or a functional part thereof and a second section comprising an oligomerising domain derived from an oligomer-forming coiled-coil protein.

Abstract: An apparatus for carrying a target object having a plurality of surfaces, within a pulsed light sterilization chamber including a treatment zone within which pulsed sterilizing light is emitted, comprises: a transmissive carrier within the treatment zone detachably coupled to the target object, the transmissive carrier having a transmissivity of at least about 10% to light within the 250 to 350 nm wavelength range; and moving means coupled to the transmissive carrier for moving the target object on the transmissive carrier through the treatment zone, the plurality of surfaces of the target object being sterilized by the pulsed sterilizing light in the treatment zone.

Abstract: Administration of an irreversible tyrosine kinase inhibitor such as CI-1033 in combination with one or more other antineoplastic agent(s), or ionizing radiation is synergistic for treating cancer.

Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.

Abstract: Water is treated by an ion exchange process that removes toxic ions, but does not significantly change the non-toxic ion concentration.

Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.

Abstract: This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula I: and Formula II: where W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R8 and R9 include hydrogen and alkyl, and Z is carboxy. This invention also provides pharmaceutical formulations comprising a compound of Formula I or II together with a pharmaceutically acceptable carrier, diluent, or excipient therefor.

Abstract: An ink reservoir container for an ink jet printer comprises an ink outlet, a first mounting location for the ink outlet, and an alternative second mounting location for the ink outlet. The container is useful in a double plumbed ink jet printer.

Abstract: An ink reservoir container for an ink jet printer comprises an ink outlet, a first mounting location for the ink outlet, and an alternative second mounting location for the ink outlet. The container is useful in a double plumbed ink jet printer.

Abstract: The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.

Abstract: An ink reservoir container for an ink jet printer comprises an ink outlet, a first mounting location being located on a print carriage for mounting the ink outlet, and an alternative second mounting location being located on the print carriage for mounting the ink outlet. The container is useful in a double plumbed print carriage of the ink jet printer.

Abstract: An inkjet printer uses large volume ink reservoir containers to supply ink to ink cartridges located on a movable print carriage. A communication link including tubing sections and quick disconnect fittings couples the large volume ink reservoir containers and the ink cartridges. The printer may be plumbed with more ink supply tubing sections than ink cartridges and ink reservoirs for the provision of different ink types. The changing of sets of large volume ink reservoir containers or sets of ink cartridges is more convenient with the use of quick disconnect fittings.

Abstract: Methods of treating proliferative diseases or viral, inflammatory, allergic and cardiovascular diseases, and restenosis are disclosed. The present invention demonstrates the use of N,N'-piperazinylbis-?2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylene-bis?2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with a substrate regulatory protein. The present invention also demonstrates the use of pharmaceutical compositions employing N,N'-piperazinylbis?2-amino-1-imidazolin-2-yl)-2-imidazolines!, 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines, and N,N'-alkylenebis-?2-amino-1-(2-imidazolin-2-yl)-2-imidazolines!, their derivatives, and salts thereof, to antagonize the association of a protein tyrosine kinase with substrate regulatory protein. The present invention also relates to novel N,N'-piperazinylbis?2-amino-1-imidazolin-2-yl)-2-imidazolines!.

Abstract: An improved process for removal of metal ions from aqueous solutions is disclosed. Removal of metal ions from aqueous solution, particularly from metal plating waste streams, is achieved by the combined use of polyamines, at levels less than the stoichiometric amount of metal ion, and cation exchangers. Treatment of waste streams with low levels of triethylenetetramine followed by contact with a strong acid cation exchange resin is especially effective in the removal of copper from metal-containing waste streams.

Abstract: Lavage apparatus including a tube member having a distal end portion and a proximate end, with a primary lumen extending axially through the tube member for flow communication between said distal end portion and the proximate end and secondary lumens extending through the distal end portion, the secondary lumens being mutually radially opposed and disposed at different distances from the distal end of the tube member to assure unobstructed flow and having the first secondary lumen disposed a distance D from the distal end of the tube member, and a radiopaque tip member extending a distance D into the primary lumen to avoid any internal spaces in which fluid may collect, the tip member also having a beveled shoulder for engaging, in compression, the distal end of the tube member to avoid any annular cavity or gaps in which fluid may collect, the tube member also having an elongate axial radiopaque strip intersecting at least the first secondary lumen to enable medical personnel to assure proper placement of th

Abstract: Acrylic anion exchange resin is used, either alone or in combination with another anion exchange resin, to purify sugar solutions of the material extracted by the solutions from sulfonated cation exchange resins. The anion exchange resin being derived by polymerization from a monomer mixture comprising polyvinyl crosslinking monomer and one or more monovinyl acrylic monomers.

Abstract: An ion exchange resin composition which comprises the reaction product of an epihalohydrin with a polyamine is alkylated. The polyamine has a molecular weight of from about 60 to about 298. This invention also encompasses a process for preparing the ion exchange resin composition which comprises reacting from about two-thirds of a stoichiometric amount of epihalohydrin to one and one-half times the stoichiometric amount of epihalohydrin with defined polyamines and thereafter reacting the resultant polymer with an alkylating agent to yield the final product.